BCS: implications on guidelines and policies for drug products approval world wide - Sponsored Whitepaper

Sponsored by:
Capsugel Logo
Capsugel
Download Entire Whitepaper
The BCS attempts to identify when dissolution rate is likely to be rate-determining, and to assess when in-vitro/in-vivo correlations would be ex- pected. And that would be, of course, the Class I type of drug, where dissolution is rapid and not the rate-determining step, plasma levels may not reflect product differences, and little or no difference would be expected between oral solutions and solid dosage forms.
Download Entire Whitepaper
Copyright © 2014, Questex Media Group LLC
Company descriptions and contact information are quoted from the company's website or other promotional information. Questex is not responsible for the accuracy of this information. Unless specifically noted, Questex is not sponsored by, affiliated with or otherwise connected with any of the listed companies.